To add to this uncertainty, there were conflicting results regarding the presence of a correlation between in vivo [18F]AV1451 binding and postmortem tau load for patients with CBS or PSP who had [18F]AV1451 imaging and neuropathological assessment of tau burden; [18F]AV1451 PET identified in vivo areas with postmortem high tau in some brain areas and patients but not others, which probably indicates a reduced sensitivity of the tracer to non-AD tau [81, 113, 115–117]. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.